Adjuvant IFN-γ therapy can restore macrophage function and provide better control of BCG-osis in patients with CGD and MSMD [29], which seems to particularly improve the prognosis for patients with IL-12Rβ1 deficiency [30]. The gene discussed is IFNG; the disease is chronic granulomatous disease.